Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Phase I/II Study of Pembrolizumab MK-3475 in Children With Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma KEYNOTE-051
Study Type: Treatment
Phase: I/II
NCTID: NCT02332668
Principal Investigator:
Jaszianne Tolbert
A Phase III, Multicenter, Randomized, Open-label, Parallel group, Treatment Study to Assess the Efficacy and Safety of the Lifileucel LN-144, Autologous Tumor-infiltrating Lymphocytes [TIL] Regimen in Combination with Pembrolizumab Compared with Pembrolizumab Monotherapy in Participants with Untreated, Unresectable or Metastatic Melanoma
Phase II/III Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator?s Choice in HLAA02:01-positive Participants with Previously Treated Advanced Melanoma TEBE-AM
Study Type: Treatment
Phase: II/III
NCTID: NCT05549297
Principal Investigator:
Gary Doolittle
A Phase III, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma
A Phase II Randomized Study of Adjuvant versus NeoAdjuvant Pembrolizumab MK-3475 for Clinically Detectable Stage III-IV High-Risk Melanoma
A PHASE II RANDOMIZED STUDY OF NIVOLUMAB (NSC-748726) WITH IPILIMUMAB (NSC-732442) OR IPILIMUMAB ALONE IN ADVANCED MELANOMA PATIENTS REFRACTORY TO AN ANTI-PD1 OR ANTI-PD-L1 AGENT
A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneious Melanoma
Study Type: Treatment
Phase: III
NCTID: NCT03860883
Principal Investigator:
Luke Selby
A Randomized, Controlled, Multicenter, Phase III Clinical Study Comparing Vusolimogene Oderparepvec in Combination with Nivolumab Versus Treatment of Physician?s Choice in Patients with Advanced Melanoma That Has Progressed on an Anti-PD-1 and an Anti-CTLA-4 Containing Treatment Regimen
Study Type: Treatment
Phase: III
NCTID: NCT06264180
Principal Investigator:
Gary Doolittle